Published: September 2012

Ondansetron: New Dose Restrictions

Prescriber Update 33(3): 21
September 2012

A new clinical study conducted by the company shows that there is a significant risk of QT prolongation in patients given high doses of ondansetron used to manage nausea and vomiting induced by highly emetogenic chemotherapy.

Consequently, the following changes and advice are recommended.

Ondansetron data sheets are currently being updated.